Six Teams to Study Managed Care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

WASHINGTON--Two federal agencies and a managed care organization are sponsoring a 3-year effort to determine how particular managed care policies affect the quality of care provided patients with chronic diseases, including protocols governing the referral of patients to medical specialists and arrangements for paying physicians.

Six research teams will receive a total of $8.5 million. The teams will be led by Jose Escarce, MD, PhD, of RAND, Santa Monica, Calif; Edward Guadagnoli, PhD, Harvard Medical School; Katherine Kahn, MD, University of California, Los Angeles; Tracy Lieu, MD, Kaiser Permanente of Northern California, Oakland; Barbara McNeil, MD; Harvard Medical School; and Elizabeth Shenkman, PhD, University of Florida, Gainesville.

The three sponsoring organizations are the Agency for Health Care Policy and Research (AHCPR) and the Health Resources and Services Administration, both parts of the HSS, and the American Association of Health Plans Foundation, which provides research for the nation’s largest managed care

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content